Kidney Biopsy in Amyloidosis: How Typing AL, AA or Hereditary Forms Shapes Treatment

The result that starts this conversation is rarely dramatic. A routine urine test comes back with far more protein than expected, ankles that felt puffy after long days now stay swollen in the morning, and a nephrologist mentions a word most people have never heard spoken aloud: amyloid. Then comes the harder sentence. To know what kind it is, we need a piece of the kidney.

A kidney amyloidosis biopsy sounds like the end of a diagnostic road. In practice it is the fork in it. The needle collects a sliver of tissue roughly the size of a pencil lead, and what the laboratory finds in that sliver decides whether the next specialist you meet is a hematologist, a rheumatologist or a genetic counselor.

This explainer walks through what the procedure involves, how pathologists tell one amyloid protein from another, and why that single distinction shapes almost everything that follows. It is written for the person sitting with a referral letter, not for the person holding the needle.

Why a kidney amyloidosis biopsy is usually the deciding test

Amyloidosis is a group of conditions in which a normally soluble protein misfolds, stacks into stiff fibers called fibrils, and lodges in tissues where it does not belong. The kidney is one of its favorite destinations. Fibrils settle in the glomeruli, the tiny filtering tufts that separate waste from blood, and the filter begins to leak protein into the urine. Over time the deposits can also thicken small blood vessels and the tubules that fine-tune salt and water.

Blood and urine tests can raise strong suspicion. They cannot see the fibrils. A biopsy can, and it does two jobs at once. First, it proves that amyloid is present rather than another cause of a leaky filter such as diabetic kidney disease or membranous nephropathy, which can look similar on paper. Second, it provides tissue that can be typed, meaning the laboratory identifies which protein built the fibrils.

That second job is the one that changes lives. According to Mayo Clinic, more than 30 proteins are known to form amyloid in humans, and the treatments for the main types differ completely. Treating a hereditary form with chemotherapy aimed at plasma cells would expose someone to serious toxicity for no benefit, while missing an AL diagnosis delays therapy that can slow the disease.

So although people often ask whether the biopsy can be skipped, the honest answer from most nephrology teams is that the kidney sample is frequently the fastest and most reliable route to both confirmation and typing when the kidney is the organ that is clearly affected. The decision, though, is individual and rests with the treating team, who weigh bleeding risk, kidney size and whether another tissue could answer the question first.

What are the early signs of renal amyloidosis?

The kidney tends to complain quietly. The earliest signal is often invisible to the person living with it: protein in the urine picked up on a dipstick at a routine visit. As the leak grows, urine may turn foamy, the way a beaten egg white froths, because protein lowers surface tension. Cleveland Clinic and NHS both describe swelling of the legs, ankles and around the eyes as common features once protein loss becomes substantial, since the blood loses the albumin that normally holds fluid inside vessels.

When protein loss becomes heavy enough, doctors use the term nephrotic syndrome, a cluster of heavy urinary protein, low blood albumin, swelling and high cholesterol. Renal amyloidosis is one of the recognized causes of nephrotic syndrome in adults, and it is often on the list when a nephrologist first sees an unexplained case.

Fatigue, reduced appetite and unintended weight loss are described across amyloid types, and they are easy to attribute to stress or age. Because amyloid rarely stays in one organ, clinicians also listen for clues elsewhere: breathlessness or an irregular heartbeat pointing to the heart, numbness or tingling in the feet pointing to nerves, an enlarged tongue or easy bruising around the eyes that Mayo Clinic lists among features of AL disease.

None of these signs is specific, which is exactly why they cannot be used to self-diagnose. Swollen ankles have dozens of causes, most of them far more common. The right response to new, persistent swelling or foamy urine is not to search for amyloidosis but to see a primary care clinician who can check the urine, measure kidney function and decide whether specialist referral is warranted. Early referral matters because the deposits already present do not simply dissolve, and the aim of treatment is to stop new ones forming.

Who is usually offered a kidney amyloidosis biopsy, and who is asked to wait

A kidney biopsy is offered when the answer will change what happens next. In amyloidosis that typically means an adult with significant unexplained protein in the urine, especially with reduced kidney function, where blood tests such as serum free light chains or protein electrophoresis suggest an abnormal plasma cell clone, or where there is a chronic inflammatory disease that raises the possibility of AA. Some people arrive from the other direction: amyloid was found in a fat sample, a bone marrow sample or the heart, and the kidney biopsy is needed to confirm renal involvement or to obtain enough tissue for typing.

Several groups are commonly asked to wait or to consider another route. The NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) notes that the procedure carries a bleeding risk, so people on anticoagulants or antiplatelet medicines are usually asked to pause them for a period set by the prescribing clinician; that pause is never a patient decision. Uncontrolled high blood pressure is corrected first because it raises bleeding risk. A severe bleeding disorder, an active kidney or skin infection, a single functioning kidney, or kidneys that have shrunk with advanced scarring may tip the balance toward a different tissue or toward treating on the basis of other evidence.

Frailty and inability to lie still and hold a breath are practical considerations, since the needle passes during a paused breath under ultrasound or CT guidance. Pregnancy prompts a careful discussion of timing.

When the kidney is not a safe target, teams often start with a fat pad aspiration or a biopsy of a more accessible organ. If that confirms and types the amyloid, the kidney sample may become unnecessary. Every one of these judgments belongs to the nephrologist, radiologist and hematologist working together with the patient.

What type of biopsy is most accurate for diagnosing amyloidosis?

The most accurate biopsy is the one taken from an organ that is clearly affected. When the kidney is leaking protein because of amyloid, the kidney sample will almost always show it, because the fibrils are precisely where the damage is happening. That is why nephrologists regard the kidney biopsy as close to a reference standard for renal amyloidosis.

Less invasive options exist and are used often. Mayo Clinic describes abdominal fat aspiration, in which a needle draws a small amount of fat from under the skin of the belly, and bone marrow sampling as ways to look for amyloid without entering a deep organ. A fat pad biopsy for amyloidosis is quick, needs only local anesthetic and carries little bleeding risk. Its weakness is sensitivity: a negative fat sample does not rule amyloid out, particularly in AA and some hereditary forms where fat involvement is less consistent. Salivary gland, rectal and skin biopsies sit in the same category of convenient but imperfect screens.

There is also the question of quantity. Typing by mass spectrometry, described below, works best with a decent amount of amyloid in the sample. A heavily involved glomerulus offers more material than a scattering of fibrils in fat.

A sensible way to think about it is a ladder. Clinicians often start on the low rung when the organ at risk is difficult or dangerous to sample, then climb only if the screen is negative or cannot be typed. When the kidney is the organ in trouble and the bleeding risk is acceptable, many teams go straight to the kidney because it answers both questions in one procedure. Which rung is right for a particular person depends on their anatomy, medicines and other organ involvement, and that is a conversation to have with the team ordering the test.

What actually happens during a kidney biopsy for amyloidosis

The procedure itself is brief, and most of the appointment is preparation and observation. MedlinePlus describes the standard percutaneous approach, meaning through the skin. You lie face down, sometimes with a pillow under the abdomen to push the kidneys toward the back. A radiologist or nephrologist uses ultrasound, occasionally CT, to locate the lower pole of the kidney, which sits away from the large vessels near the center.

The skin is cleaned and numbed with local anesthetic. You will feel pressure rather than sharp pain, and you may be asked to hold your breath for a few seconds while a spring-loaded needle takes a core. It makes a distinct click, which surprises people more than it hurts them. Two or three cores are usually collected so that separate pieces can go to light microscopy, immunofluorescence and electron microscopy. In amyloidosis a portion may be set aside for mass spectrometry.

Sedation is not routine, though a mild relaxant can be offered to someone who is anxious. A transjugular approach, threading a catheter through a neck vein to the kidney, is reserved for people at high bleeding risk and is performed by an interventional radiologist. Open surgical biopsy is now rare.

Afterward you lie on your back, often for several hours, while nurses check blood pressure, pulse and the color of your urine. NIDDK notes that some centers keep people overnight, particularly if they live far away or have reduced kidney function, while others discharge the same day once observations are stable. The tissue reaches the pathology laboratory that day, but the full typed report typically follows over the next one to two weeks according to Mayo Clinic’s account of biopsy results, and longer if specialized protein analysis is needed.

How pathologists confirm amyloid and then type it

Confirmation comes first. Under ordinary staining, amyloid appears as smooth, glassy, pink material filling parts of the glomeruli and lining small arteries. That appearance suggests amyloid but does not prove it. The proof is Congo red, a dye that binds to the repeating structure of amyloid fibrils. When the stained slide is viewed under polarized light, the deposits glow a distinctive apple green, a property called birefringence that Mayo Clinic and MedlinePlus both describe as the classic laboratory signature. Electron microscopy adds a second confirmation by showing the fibrils themselves as randomly arranged, non-branching fibers.

Typing comes next, and this is where laboratories differ. Immunofluorescence, in which antibodies tagged with fluorescent dye are applied to the tissue, is routine in kidney pathology. If the deposits light up strongly for one type of immunoglobulin light chain, kappa or lambda, and not the other, AL is likely. If they stain for serum amyloid A protein, AA is likely. Immunohistochemistry uses the same principle with a color reaction visible under a normal microscope.

Antibody-based typing has limits. Amyloid fibrils are often fragments of the parent protein, and antibodies may bind poorly or bind to background proteins trapped in the deposit. Equivocal results are common enough that many centers now use laser microdissection with mass spectrometry: the amyloid is cut out of the slide with a laser, digested, and its proteins identified by their exact molecular weights. This method can distinguish AL from AA from transthyretin from rarer proteins such as leukocyte chemotactic factor 2 (ALECT2) or fibrinogen A alpha chain, and it does not depend on an antibody being available.

Your amyloidosis kidney biopsy results, therefore, may arrive in stages: a preliminary confirmation, then a typed report. Ask which method was used and how confident the pathologist is.

AL, AA and hereditary amyloidosis compared

The three groups most often found in kidney tissue share a stain and little else. Their origins, the specialists who treat them and the goals of treatment all differ, and a side-by-side view makes the logic of typing clear.

Feature	AL amyloidosis	AA amyloidosis	Hereditary amyloidosis
Protein forming fibrils	Immunoglobulin light chain (kappa or lambda)	Serum amyloid A, a liver protein raised by inflammation	Mutated inherited protein: transthyretin, fibrinogen A alpha, apolipoprotein AI, lysozyme, gelsolin and others
Underlying driver	Abnormal plasma cell clone in bone marrow	Long-standing inflammation or infection	Gene variant passed through families
Organs beyond kidney	Heart, nerves, gut, liver, soft tissue	Mostly kidney; gut, liver, spleen	Varies by protein; nerves and heart in transthyretin, kidney in fibrinogen forms
Main treatment aim	Suppress the clone producing light chains	Control the inflammatory source	Reduce or stabilize the faulty protein; genetic counseling
Lead specialist	Hematologist with nephrologist	Rheumatologist or infectious disease with nephrologist	Amyloid specialist, geneticist, nephrologist

The table also shows why a mistake is costly in both directions. A person with hereditary fibrinogen amyloidosis who is mislabeled as AL would face plasma-cell-directed therapy that cannot touch the real cause. A person with AL whose deposits are dismissed as hereditary loses time during which light chains keep arriving in the kidney and, often, the heart.

Not every case fits a box. Some kidneys show more than one process, such as AA amyloid alongside a separate immune-mediated glomerular disease, and ALECT2 amyloidosis, which is not clearly inherited or inflammatory, is recognized increasingly in kidney biopsies from particular populations. When a case does not fit, teams tend to repeat typing with a second method before committing to a treatment plan, and that caution is a sign of good practice rather than indecision.

How AL amyloidosis kidney treatment follows from the biopsy

In AL amyloidosis the villain is upstream of the kidney. A small population of plasma cells in the bone marrow manufactures a light chain that misfolds, and every day it continues, new fibrils reach the glomeruli and, frequently, the heart. Treatment is therefore aimed at the factory, not the deposits. NHS and Mayo Clinic describe this approach as similar to therapy for multiple myeloma, using medicines that kill or suppress plasma cells.

The classes involved include proteasome inhibitors, which block the cell’s protein-recycling machinery so that plasma cells choke on their own output; alkylating chemotherapy agents; corticosteroids; and monoclonal antibodies directed against CD38, a surface marker on plasma cells. For some people, high-dose chemotherapy followed by a transplant of their own stem cells is considered, but eligibility depends heavily on heart function and general fitness, and many people with kidney involvement are judged unsuitable. These are descriptions of how the treatments work, not recommendations; the choice, sequence and duration belong to the hematologist.

Response is judged in two layers. The hematologic response is measured by blood tests tracking the light chain, often within weeks to a few months of starting therapy. The organ response comes later, as urinary protein falls and kidney function stabilizes, and Mayo Clinic notes that improvement in affected organs can take considerably longer than the blood response because the existing deposits clear slowly if at all.

The biopsy influences more than the drug choice. It shows how much scarring accompanies the amyloid, which helps the team judge how much kidney function can realistically be preserved, and whether early planning for dialysis or transplantation is prudent. It also identifies people whose kidney amyloid is AL even when the heart is the more visible problem, which matters because kidney function affects how some medicines are handled.

How AA and hereditary forms are treated once typed

AA amyloidosis is a disease of persistence. Serum amyloid A is a normal protein the liver releases during inflammation, and in most people it rises and falls harmlessly. When inflammation runs for years, as in poorly controlled rheumatoid arthritis, inflammatory bowel disease, chronic infections such as bronchiectasis or tuberculosis, or inherited autoinflammatory syndromes such as familial Mediterranean fever, the protein stays high and fibrils accumulate, most often in the kidney. Treatment logic follows directly: find the source and bring the inflammation down. That may mean biologic medicines that block tumor necrosis factor or interleukin-1 or interleukin-6, treating an infection, or adjusting therapy for the underlying condition. Cleveland Clinic and NHS frame the aim as controlling the inflammatory disease so that production of the amyloid precursor falls. Blood levels of serum amyloid A or C-reactive protein become the monitoring tool.

Hereditary amyloidosis divides by protein. Transthyretin-related disease, which mainly affects nerves and heart, has medicines that stabilize the transthyretin molecule so it cannot misfold, and others that silence the gene message so the liver makes less of it; kidney involvement is uncommon but recognized. Fibrinogen A alpha chain amyloidosis targets the kidney almost exclusively and has historically been managed with kidney transplantation, sometimes with consideration of the liver as the protein’s source. Apolipoprotein AI, lysozyme and gelsolin forms are rarer still and are usually cared for in specialist amyloid centers.

Two consequences follow a hereditary result. Genetic counseling is offered, because first-degree relatives may carry the same variant, and some variants show late or incomplete penetrance, meaning not everyone who carries them becomes ill. And the hematology workup is often stood down, sparing the person treatment they never needed. That is the practical payoff of careful typing.

What the days and weeks after a kidney biopsy usually look like

The first evening is mostly rest and observation. A dull ache at the puncture site, on the back just below the ribs, is expected and usually settles within a day or two. A little blood in the urine is common; MedlinePlus notes it typically clears within a few days. Nurses will explain how to check the small dressing and when to remove it.

For the first 24 hours most teams ask you to take it easy and avoid driving. NIDDK advises avoiding strenuous activity, heavy lifting and vigorous exercise for around two weeks, because the kidney needs time to seal the needle track and a strain can restart bleeding. Desk work can often resume within a couple of days; physically demanding work may need a longer pause agreed with the clinician who performed the biopsy.

Medicines that were paused, particularly blood thinners and aspirin-type drugs, are restarted only when the prescribing clinician says so. Do not restart them on your own schedule, and do not stop anything else without asking.

The results arrive in layers. A preliminary reading confirming amyloid may come within days; the typed report, especially if mass spectrometry is used, more often takes one to two weeks and sometimes longer, in line with Mayo Clinic’s general guidance on biopsy turnaround. During this wait the team usually completes the rest of the staging: heart ultrasound and cardiac blood markers, serum free light chains, a search for an inflammatory source, and, if hereditary disease is suspected, a genetic test. The follow-up appointment where the biopsy is explained is the moment to bring a written list of questions and, ideally, a second pair of ears.

What is the prognosis for amyloidosis in the kidney, and how serious is it?

Amyloidosis is a serious diagnosis, and it would be dishonest to soften that. It is also far more variable than the word implies, and the two factors that shape the outlook most are the type of amyloid and whether the heart is involved. Mayo Clinic and NHS are consistent on this point: in AL disease, cardiac involvement is the strongest driver of prognosis, and people whose heart is spared or only mildly affected generally do better than those with advanced cardiac deposits. The biopsy cannot measure that directly, which is why heart tests always accompany it.

Kidney-specific outlook depends on how much function remains at diagnosis and how much protein is leaking. Heavy protein loss and an already reduced filtration rate raise the likelihood that dialysis will eventually be needed. Scarring seen on the biopsy alongside the amyloid is a marker of damage that will not reverse. On the other hand, when the underlying driver is controlled early, protein loss can fall and kidney function can stabilize for long periods, and many people with AA disease whose inflammation is brought under control, or with AL disease that responds well to plasma-cell therapy, live with stable kidney function for years.

Specific survival figures are not quoted here on purpose. Published numbers vary widely by type, stage, era of treatment and the population studied, and a figure without its context misleads more than it informs. Your team can give you an individualized estimate using your type, your heart markers and your kidney numbers, and that estimate is the one that matters.

Dialysis and kidney transplantation remain options if kidney failure develops. Transplantation is considered when the underlying amyloid process is controlled, since deposits can recur in a new kidney if the source is still active.

What people often get wrong about a kidney amyloidosis biopsy

“If the blood test shows a light chain problem, the biopsy is just a formality.” Abnormal light chains are common in older adults without amyloidosis, and a person can have an unrelated plasma cell clone alongside AA or hereditary amyloid. Tissue typing is what prevents treating the wrong disease.

“A negative fat pad biopsy means I do not have amyloidosis.” Fat aspiration is a convenient screen, but Mayo Clinic and other sources describe it as less sensitive than biopsy of an affected organ, particularly in non-AL types. A negative fat sample in someone with unexplained heavy proteinuria still leaves the kidney question open.

“Amyloid is a kind of cancer.” AL amyloidosis arises from a plasma cell clone and is treated by hematologists with medicines borrowed from cancer care, but the deposits themselves are misfolded protein, not tumor tissue, and AA and hereditary forms have nothing to do with cancer at all.

“The biopsy will damage my already weak kidney.” The needle removes tissue about the size of a pencil lead from an organ containing roughly a million filtering units. The meaningful risk is bleeding, not loss of function, and NIDDK describes serious bleeding requiring transfusion or a procedure as uncommon.

“Once the amyloid is typed, treatment will remove the deposits.” Current treatments aim to stop new fibrils forming. Existing deposits clear slowly and incompletely, which is why symptoms may lag behind blood test improvements by months.

“Hereditary means everyone in the family will get it.” Many amyloid gene variants show incomplete penetrance, so carrying the variant does not guarantee disease. Genetic counseling exists precisely to explain what a result does and does not mean for relatives.

Questions to ask your care team before and after the biopsy

A good consultation leaves you knowing not just what was found but how sure the team is and what would change their mind. The questions below are a starting point; adapt them to your situation and bring them in writing, because the appointment after a biopsy tends to be dense.

• Why is a kidney biopsy preferred over a fat pad or bone marrow sample in my case, and what would you do if the kidney sample could not be typed?
• Which of my medicines need to be paused before the procedure, for how long, and who will tell me when to restart them?
• How many cores will be taken, and will tissue be reserved for mass spectrometry if the antibody staining is unclear?
• Was the amyloid typed by immunofluorescence, immunohistochemistry or mass spectrometry, and how confident is the pathologist in the result?
• How much scarring was seen alongside the amyloid, and what does that tell you about my kidney’s outlook?
• Which other organs have you checked or plan to check, particularly the heart, and how will those results change the plan?
• If this is AL, which specialist leads my care and how will we know whether treatment is working, in blood tests and in kidney measures?
• If this is AA, what do you believe the inflammatory source is, and how will you monitor whether it is controlled?
• If this is hereditary, who should be offered genetic counseling, and is testing of relatives recommended now or later?
• What would prompt you to repeat the biopsy or send the tissue to a specialist amyloid laboratory?
• Is there anything about my kidney function that affects which treatments are safe for me?

You are entitled to ask for a copy of the pathology report. Reading it with the team, line by line, is often the moment the diagnosis stops being abstract.

When to call your doctor

Most kidney biopsies pass without incident, but bleeding is the complication that matters, and it can appear hours or occasionally days after you leave. MedlinePlus and NIDDK advise urgent contact with the biopsy team or emergency services if you notice any of the following: urine that turns bright red or contains clots, or blood in the urine that has not faded after a few days; pain at the biopsy site or in the flank that is severe, worsening, or not relieved by the pain relief you were advised to use; inability to pass urine; dizziness, faintness, a racing heart or feeling cold and clammy, which can signal internal bleeding; fever or chills, or redness, warmth and discharge at the puncture site, which suggest infection.

Beyond the procedure itself, the amyloidosis calls for its own vigilance. Contact your team promptly if swelling increases rapidly, if you gain weight quickly over a few days, if you become breathless lying flat or wake at night short of breath, if your urine output falls noticeably, or if you develop new palpitations, chest discomfort or fainting spells. These can indicate that fluid is accumulating or that the heart is involved, and they need assessment rather than waiting for the next scheduled visit.

If you have started treatment, report new infections, persistent nausea or diarrhea, unusual bruising, or numbness and tingling that is new or spreading. Many of the medicines used in AL and AA disease have recognized side effects that are easier to manage when caught early, and dose or regimen changes are decisions for the prescribing clinician, never something to adjust alone.

When in doubt, call. Nephrology and hematology teams would rather hear about a symptom that turns out to be nothing than learn about one late.

Frequently asked questions

What is the prognosis for patients with amyloidosis in the kidney?

The outlook varies widely and depends mainly on the type of amyloid, how much kidney function remains at diagnosis, and whether the heart is involved. In AL disease cardiac involvement is the strongest determinant of prognosis, while in AA disease controlling the underlying inflammation can stabilize kidney function for years. Published survival figures differ so much by type and stage that a single number is misleading; your team can give an individualized estimate.

How serious is amyloidosis?

Amyloidosis is a serious condition because misfolded protein accumulates in organs and does not readily clear, and untreated it can lead to kidney failure or heart failure. Seriousness differs by type and by which organs are involved. Early typing and treatment aimed at the source of the protein can slow or halt new deposits, which is why prompt referral after unexplained heavy proteinuria matters.

What type of biopsy is most accurate for diagnosing amyloidosis?

A biopsy of an organ that is clearly affected, such as the kidney in someone with heavy proteinuria, is the most reliable, because the fibrils are concentrated where the damage is occurring and there is enough material for typing. Fat pad aspiration, bone marrow and salivary gland samples are less invasive screens, but a negative result from these does not rule amyloidosis out.

What are the early signs of renal amyloidosis symptoms people notice first?

The earliest sign is usually protein in the urine detected on a routine test before any symptoms appear. As protein loss grows, urine may become foamy and swelling develops in the ankles, legs and around the eyes. Fatigue, reduced appetite and weight loss are common but nonspecific. Because these features have many causes, persistent swelling or foamy urine should prompt a visit to a clinician rather than self-diagnosis.

Is a fat pad biopsy for amyloidosis enough, or will I still need a kidney biopsy?

It can be enough when it confirms amyloid and provides adequate material for reliable typing, in which case the kidney biopsy may be avoided. When the fat sample is negative, too scant to type, or gives an equivocal result, and the kidney is the organ in trouble, most teams proceed to a kidney biopsy. The decision depends on your bleeding risk, kidney size and other organ findings.

How long does it take to get amyloidosis kidney biopsy results?

A preliminary reading that confirms amyloid may be available within a few days, while the fully typed report more often takes one to two weeks, in line with general biopsy turnaround times described by Mayo Clinic. If the tissue is sent for laser microdissection and mass spectrometry, or to an external specialist laboratory, the wait can be longer. Your team will usually complete heart and blood staging during this period.

What does AL amyloidosis kidney treatment involve?

Treatment targets the abnormal plasma cells producing the misfolded light chain, using classes such as proteasome inhibitors, alkylating chemotherapy, corticosteroids and anti-CD38 monoclonal antibodies, with stem cell transplantation considered for selected fit patients. Response is tracked first in blood light chain levels and later in urinary protein and kidney function. Specific regimens, sequencing and duration are decisions for the treating hematologist.

Can a kidney biopsy tell if amyloidosis is hereditary?

It can point strongly toward a hereditary form when mass spectrometry or immunohistochemistry identifies a protein such as transthyretin, fibrinogen A alpha chain or apolipoprotein AI in the deposits. Confirmation requires a genetic blood test to identify the specific variant. A hereditary result usually leads to genetic counseling for the patient and, where appropriate, relatives, and it typically ends the search for a plasma cell cause.

What are the risks of a kidney biopsy in amyloidosis?

Bleeding is the main risk, ranging from mild blood in the urine that clears within days to, uncommonly, bleeding that needs a transfusion or a procedure to stop it. Pain at the site, infection and, rarely, injury to nearby structures are also possible. Some clinicians consider bleeding risk slightly higher in amyloidosis because amyloid can affect vessel walls, so blood pressure control and pausing blood thinners are handled carefully beforehand.

Can amyloid come back in a transplanted kidney?

Yes, deposits can recur in a new kidney if the source protein is still being produced, which is why transplantation is usually considered once the underlying process is controlled, for example after a good response to plasma-cell therapy in AL disease or sustained suppression of inflammation in AA disease. Hereditary forms are assessed individually, since the faulty protein continues to be made by the liver or other tissue.

References

• MedlinePlus: Renal biopsy
• NHS: Amyloidosis
• Cleveland Clinic: Amyloidosis
• NIH NIDDK: Kidney biopsy

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.